[Chronic heart failure--the epidemic of the 21st century].
Heart failure represents a major public health problem in the industrialized countries and despite of optimal medical treatment its mortality remains high. The history of its management reflects growth and changes in our understanding of its pathophysiology. In the past, pharmacological treatment of heart failure was aimed only at relieving edema and improving hemodynamics. Today, however, a major aim of treatment is to antagonize the sympathetic nervous system and renin-angiotensin-aldosterone system, to avert harmful effects of neurohormonal activation on the myocardium and peripheral vessels. Currently, the major pharmacological treatments for heart failure are diuretics, ACE inhibitors, beta-blockers and (in NYHA classes III-IV) aldosterone antagonists. Some patients may also require specific treatment with additional drugs (e.g. anti-arrhythmia agents, anticoagulants, or vasodilators) or procedures such as coronary revascularization, or implantable devices such as pacemakers and implantable cardioverter defibrillators, or resynchronization devices. Patients with end-stage heart failure may require cardiac transplantation or ventricular assist devices. This review is summarized the recent practical drug therapy of heart failure and the results of the newer clinical trial.
Czuriga
István
I
Debreceni Egyetem, Orvos- és Egészségtudomnyi Centrum, Altalános Orvostudományi Kar, Kardiológiai Intézet. iczuriga@jaguar.dote.hu
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002908:Chronic Disease; D017147:Defibrillators, Implantable; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D004921:Erythropoietin / Q000627:therapeutic use; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D006353:Heart-Assist Devices; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D007155:Immunologic Factors / Q000627:therapeutic use; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D010138:Pacemaker, Artificial; D010447:Peptide Hydrolases / Q000187:drug effects; D011322:Primary Prevention / Q000379:methods; D012307:Risk Factors; D012720:Severity of Illness Index; D014667:Vasopressins / Q000037:antagonists & inhibitors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004071:Digitalis Glycosides; D004232:Diuretics; D065128:Endothelin Receptor Antagonists; D007155:Immunologic Factors; D000451:Mineralocorticoid Receptor Antagonists; D014667:Vasopressins; D004921:Erythropoietin; D000804:Angiotensin II; D010447:Peptide Hydrolases